CTIX has been showing support at 1.33 and resistance at 1.6946. Technicals are showing great signs of upside potential. http://www.allotcbb.com/quote.php?symbol=ctix
Bouncing off support at $1.24. Technical turning up. Could go higher. Resistance: 1.6293 http://www.allotcbb.com/quote.php?symbol=ctix
Cellceutix Corporation Announces Industry Veteran Arthur P. Bertolino, MD, PhD, MBA Joins Company as President and Chief Medical Officer BEVERLY, MA–(Marketwired – June 30, 2016) - Cellceutix Corporation, (OTC: CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, today announces the appointment of Arthur P. Bertolino, MD, PhD, MBA, as President and Chief Medical Officer. Dr. Krishna Menon will continue to serve as Chief Scientific Officer and President of Research at Cellceutix. Dr. Bertolino is a leading pharmaceutical executive with over fifteen years of domestic and international drug development and management experience. Dr. Bertolino’s responsibilities will include, but are not limited to, day-to-day operations for all aspects of the Company, including pipeline development, cohesion of clinical and business strategies, team building and exploration of partnering opportunities. In his career, Dr. Bertolino held several key positions at Novartis Institutes for Biomedical Research (NIBR), including Vice President of Dermatology and Vice President & Global Head of Translational Medicine for Dermatology. During his time at NIBR, Dr. Bertolino was integral to the marketing approval of Ilaris® (canakinumab) in the United States, European Union and Switzerland. He also led the early clinical program of Cosentyx™ (secukinumab) and late stage supportive submission studies. Further, he successfully recruited an additional six physicians to the Novartis team and contributed to other hires in NIBR. Dr. Bertolino held positions as Senior Medical Director and Senior Director of Dermatology at Pfizer, Inc. Among other accomplishments at Pfizer, he led clinical programs for over a half-dozen new chemical entities involving Phase 1 and Phase 2 studies and contributed to planning for Phase 3 studies. Dr. Bertolino led FDA clinical interactions at entitlement meetings for Pfizer’s dermatology products and served as Pfizer’s dermatology spokesperson. Dr. Bertolino served as Chief Medical Officer and Vice President of Medical Affairs at Peplin, Inc., where he led Phase 2 programs and designed and drove initial Phase 3 programs that contributed to FDA approval of Picato® (ingenol mebutate). Dr. Bertolino also held the position of Executive Vice President and Chief Medical Officer at Revance Therapeutics, where he, among other responsibilities, supervised all aspects of clinical staff and programs and regulatory affairs. Dr. Bertolino earned a BS in Chemistry/Biochemistry from SUNY Stony Brook, an MD and PhD in Pharmacology from The Johns Hopkins University School of Medicine, and an MBA from the University of Michigan Stephen M. Ross School of Business. He has authored over 50 abstracts, papers, and book chapters, and also has been a contributor to major media broadcasts and print media, such as Nightline, Nova, CBS This Morning, Men’s Health, GQ, Discover and more. “With several of our compounds in or approaching mid- and late-stage development, we are assembling a team of industry veterans with a track record of bringing drugs to market. Art is an important first addition in these efforts as we recruit and negotiate with other industry leaders to advance our novel therapies for patients in need around the world. He brings exceptional clinical and corporate leadership and regulatory expertise, having spearheaded multiple development programs for drugs forecasted to be blockbusters for some of the world’s most recognized pharmaceutical companies,” commented Chief Executive Officer Leo Ehrlich. “Art will play a pivotal role as we seek to realize the global potential of the entire Cellceutix pipeline.” Dr. Bertolino commented, “I am excited to join Cellceutix. While many professional opportunities were presented to me, I saw Cellceutix as the best fit and an exciting opportunity to lead the advancement of what I believe are some very promising drug candidates. The Company’s pipeline is world-class, with compounds that can transform lives. I look forward to helping Cellceutix deliver on its vast potential.” - See more at: http://cellceutix.com/cellceutix-co...d-chief-medical-officer/#sthash.fhuVBQF6.dpuf
Cellceutix to Initiate Phase 2b Trial of Prurisol for Chronic Plaque Psoriasis BEVERLY, MA–(Marketwired – July 07, 2016) - Cellceutix Corporation, (OTC: CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to provide shareholders information on the next phases of clinical and corporate development following the recent appointment of Arthur P. Bertolino, MD, PhD, MBA as President and Chief Medical Officer. “As I become even more familiar with the Cellceutix staff and pipeline, I continue to see a great deal of value and potential in our three lead compounds: Kevetrin, Brilacidin and Prurisol,” commented Dr. Bertolino. “I am working full-time with our team to define succinct clinical development strategies to advance these programs in a manner proven successful in my previous pharmaceutical experiences. My current emphasis is centered on efficient drug development and recruiting additional leading industry veterans for our staff and advisory board to assist in these matters. I believe this will translate into sustainable value for our company.” Since successfully completing the initial Phase 2 trial of oral Prurisol for mild to moderate plaque psoriasis, the Company has fielded inquiries from many interested parties about the compound and has evaluated several options for the next stage of development. After a detailed analysis, the data clearly show that the most robust response to Prurisol was in patients with moderate psoriasis in the trial’s highest dosing arm (200mg), with no serious adverse events reported. Benefits were apparent by two weeks and showed further improvement by the end of the study at 12 weeks. Cellceutix has begun preparing for a Phase 2b trial of Prurisol for patients with moderate to severe plaque psoriasis in order to better define appropriate dosing to achieve greatest clinical responses. The Company intends to increase the dosing beyond 200mg and evaluate patients using the Psoriasis Area and Severity Index (PASI) scoring method, which will enable better comparison to approved psoriasis drugs, including apremilast and biologics. In addition to evaluating efficacy in moderate to severe psoriasis, multiple secondary endpoints will be studied to provide insights regarding additional potential benefits of Prurisol compared to approved therapies. Our expectations are to initiate the trial late in the third quarter or early in the fourth quarter with top-line results in the second quarter of 2017. “There is a significant opportunity in successfully developing a potent oral drug for chronic psoriasis. The spectrum of current treatment options spans multiple injectable biologics, oral apremilast, and a variety of topical creams,” said Dr. Bertolino. “A new oral drug that delivers substantial efficacy should command considerable market value and further attract the attention of pharmas looking to expand their dermatology offerings. I believe that Prurisol has that potential and that a refined second successful Phase 2 trial would further anchor the value that we already appreciate.” “As we further define plans in the coming weeks for the development of Brilacidin and Kevetrin, we intend to also provide shareholders with additional updates on our clinical and pre-clinical program strategies,” concluded Dr. Bertolino. - See more at: http://cellceutix.com/cellceutix-to...hronic-plaque-psoriasis/#sthash.HaCE3CBj.dpuf
Cellceutix Recieves Update on First Patient Enrolled in Phase 2 Proof-of-Concept Study of Brilacidin for Ulcerative Proctitis Company Encouraged by Investigator Report of Significant Decrease in Symptoms in First Patient in One Week BEVERLY, MA–(Marketwired – July 18, 2016) - Cellceutix Corporation, (OTCQB: CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to provide additional information in the ongoing, open-label Phase 2 Proof-of-Concept (P-o-C) trial of Brilacidin for the treatment of ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS). Brilacidin is being evaluated in adults with active, mild to moderate UP or UPS present for at least three months prior to screening with disease extending at least five centimeters, but no further than 40 centimeters from the anal verge, as confirmed by sigmoidoscopic examination. Cellceutix has been advised that the first patient in Cohort A remains on study. The clinical site administering Brilacidin to this patient has informed the Company, “Both the patient and the site staff have been amazed how the study drug works as all the symptoms decreased significantly within the 1st week of treatment.” While impressed and optimistic about the initial feedback, Cellceutix needs to strongly caution that this is limited feedback from only the first patient in the trial and the initial results may not be durable for the patient or indicative of future outcomes in the study. “The trial being structured as an open-label study lets us know with certainty that Brilacidin was administered to the patient and not a placebo,” commented Dr. Arthur P. Bertolino, President and Chief Medical Officer at Cellceutix. “It’s still very early in the study, but this is the type of investigator feedback that is encouraging to hear. While by no means guaranteeing future results, it lends validation to laboratory research that suggested Brilacidin could provide a clinically meaningful therapeutic benefit for patients with UP, UPS and other inflammatory diseases and conditions. We are hopeful that the initial data will translate to durable and repeated results throughout the first cohort and subjects at higher dosing levels to align us for larger trials in the future.” Cellceutix considers this early study information important as the Company has made a significant investment in studying the anti-inflammatory and immunomodulatory properties of Brilacidin for several different indications. Due to the pathogenesis of UP and UPS, Cellceutix views this data as strongly encouraging evidence of the anti-inflammatory and immunomodulatory properties of Brilacidin in the clinical setting. The data are pertinent with respect to not only inflammatory bowel conditions, but also to the ongoing, double-blind Phase 2 trial of Brilacidin-OM, where the combination of these properties is expected to deliver a clinical benefit to prevent and treat oral mucositis in patients receiving chemoradiation for head and neck cancer. UP/UPS Trial Design The primary objective of the P-o-C trial is to assess the frequency of clinical and endoscopic remission with Brilacidin administered per rectum in subjects with active UP or UPS after 6 weeks of treatment. Secondary objectives include evaluation of safety and tolerability of Brilacidin when administered per rectum, evaluation of clinical remission at Week 2 and Week 4, assessment of systemic exposure and/or pharmacokinetics of Brilacidin when administered per rectum, assessment of the efficiency of Brilacidin by biomarker evaluation of biopsy samples for interleukin (IL)-6 and IL-1beta, and estimation of statistical power for subsequent trial(s) in UP and UPS. The P-o-C trial will include 18 patients divided evenly into three cohorts. Cohort A is receiving 50 milligrams (mg) of Brilacidin once daily for 42 days. Dosing will be increased to 100mg and 200mg once daily for 42 days for Cohort B and Cohort C, respectively. Endoscopic evaluation of the rectum and mucosa up to 40 cm from the anal verge will be performed at screening and at the end of treatment/Day 42 (± 3 days). Per protocol, a safety committee will review safety and retention data (clinical laboratory findings, vital signs and adverse events) after 21 days of therapy for all six patients in each cohort before proceeding with initiating enrollment in the subsequent cohort. - See more at: http://cellceutix.com/cellceutix-re...or-ulcerative-proctitis/#sthash.9rRTbb0w.dpuf
Cellceutix Expedites Phase 2 Trial of Brilacidin-OM for Oral Muscositis BEVERLY, MA –(Marketwired – July 21, 2016) - Cellceutix Corporation, (OTCQB: CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to provide additional information in the ongoing, Phase 2 clinical trial of Brilacidin-OM for the treatment of oral mucositis (OM), a serious and debilitating complication of radiation and chemotherapy for head and neck cancer. Cellceutix has recently retained several experienced OM consultants and embarked on a rapid expansion of the study with a goal of completing its study enrollment on an expedited basis. The Company also has been advised that a competing OM trial, which announced recently that it is being discontinued, has resulted in the availability of a large number of clinical sites, that are being considered to participate in the Cellceutix trial. Cellceutix expansion of the study assures that it will be working with sites and investigators possessing a keen understanding of the unique challenges of OM trials and a proven track record of reliable patient recruitment and retention. “Cellceutix is committed to completing its ongoing study of Brilacidin-OM for the benefit of patients at risk for developing oral mucositis and we are optimistic that the promising preclinical results from an established and predictive laboratory animal model will be replicated in this study,” commented Dr. Arthur P. Bertolino, President and Chief Medical Officer at Cellceutix. “While we can never predict with certainty what will happen when we transition from the laboratory to the clinic, we certainly can take steps to expedite the clinical trial process and maximize the probability of success. We are pleased to have engaged groups with proven track records to get us to the finish line in an efficient and capable manner.” As disclosed on Monday, July 18, 2016, Cellceutix received positive feedback from the first patient treated in a Phase 2 Proof-of-Concept (P-o-C) trial of Brilacidin for ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS). While this commentary was only for one patient, it is relevant to Cellceutix management and shareholders, as OM, UP and UPS are all conditions where inflammation plays a significant role. The open-label design of the P-o-C trial, compared to the double-blind design of the OM trial, was the first opportunity for Cellceutix to know with certainty that the subject was treated with Brilacidin. Albeit very early feedback, the Company views the positive feedback as supportive of the anti-inflammatory properties demonstrated in the preclinical research of Brilacidin and the potential for these properties to help patients with OM. - See more at: http://cellceutix.com/cellceutix-ex...n-om-for-oral-mucositis/#sthash.Ymrnqonc.dpuf
New Cellceutix Report out for those that missed it last week. Very comprehensive report. Well done. http://www.mpadvisor.com/xyz/Cellceutix_160826.pdf
Cellceutix Begins Phase 2b Clinical Trial of Oral Prurisol in Moderate-to-Severe Chronic Plaque Psoriasis BEVERLY, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) — Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, is pleased to announce today that it has begun the screening of patients in its Phase 2b clinical trial of oral Prurisol for the treatment of moderate-to-severe chronic plaque psoriasis. This clinical trial is a randomized, double-blind, parallel-group, placebo-controlled study with approximately 189 patients anticipated to be enrolled. Treatment groups include oral Prurisol 300mg per day, oral Prurisol 400mg per day, and placebo (3:1:3 randomization, respectively). Duration of treatment is 12 weeks (84 days), with a post-treatment follow-up appointment 4 weeks after the end of treatment. The study is being conducted at approximately 30 sites throughout the United States. This Phase 2b study increases the total daily dosing of Prurisol above 200mg, the maximum level used in our previously successful Phase 2 trial, which showed the drug candidate to be a promising treatment for psoriasis. Primary efficacy will be evaluated using the Psoriasis Area and Severity Index (PASI), enabling a more direct comparison to already approved psoriasis drugs. In addition, multiple secondary endpoints will be studied to provide further insights into the potential benefits of Prurisol compared to marketed therapies, both oral and biologic. “We look forward to efficient execution of this important trial for our psoriasis program. Having partnered with one of the premier CROs in the Dermatology therapy area for this study, I am confident that we will be able to assess interim and final study results in a timely fashion,” said Jane Harness, Cellceutix VP, Clinical Sciences and Portfolio Management. “The start of this study is a key milestone for our psoriasis program, bringing us closer to the Phase 3 registration program, and its results will further build upon the positive Phase 2 data reported earlier this year,” said Arthur P. Bertolino, MD, PhD, MBA, Cellceutix President and Chief Medical Officer. “A new oral drug that delivers substantial efficacy, expanding choices for treatment, should command considerable market value and add value for our shareholders.” Leo Ehrlich, Chief Executive Officer of Cellceutix, commented: “This study is yet another example of the momentum emerging across our clinical portfolio of first-in-class drug candidates. Cellceutix continues to deliver diverse milestones. As to the Dermatology therapy area, multiple recent acquisitions by Big Pharma of companies with innovative therapies convince us that the Company’s strategic positioning is significantly strengthened as we make progress in this area.” Cellceutix anticipates conducting an interim analysis of 6-week data from this Phase 2b trial in chronic plaque psoriasis with readout available in 2Q2017 and full study top-line results in 3Q2017. Alerts: Sign-up for Cellceutix email alerts is available at http://cellceutix.com/email-alerts/#sthash.pWCBhC9U.dpbs About Prurisol Acting through immune modulation and PRINS reduction, Prurisol is a novel dermatology compound currently in mid-stage development as an oral psoriasis treatment utilizing the advantages of the FDA’s 505(b)(2) development approach. This regulatory approach helps expedite a drug candidate’s approval as it allows the FDA to rely, in part, on existing clinical data from an already approved drug, in this instance, Ziagen. In laboratory studies, Prurisol was found to be effective against psoriasis in animal models, both in induced psoriasis and in a xenograft model using human psoriatic tissue. In these models, Prurisol eliminated virtually all signs of psoriasis. Cellceutix has successfully completed a Phase 2 clinical trial of Prurisol in patients with mild-to-moderate chronic plaque psoriasis. Overall analyses showed that the drug candidate appears to be safe, well-tolerated and efficacious in the highest dosing arm across 12 weeks of treatment. Patients with moderate psoriasis saw the greatest clinical improvements. An early (by week two) dose-dependent response that improved as treatment duration increased was observed. Cellceutix has initiated a Phase 2b clinical trial of Prurisol in moderate-to-severe psoriasis and will be assessing the drug candidate’s efficacy at higher dosing regimens. About Psoriasis Affecting an estimated 125 million people worldwide, psoriasis is a chronic immune-mediated skin disorder presenting with varying symptoms and levels of severity. The condition is characterized by raised and inflamed skin, often on the elbows, knees, scalp, hands and feet, causing itching, irritation, stinging and pain. Often feeling socially stigmatized, over 80 percent of people with psoriasis report it negatively impacts the quality of their everyday life. Cases are graded as Mild, Moderate and Severe depending upon extent of body surface area involved as well as other parameters. Up to 30 percent of psoriasis patients will eventually develop psoriatic arthritis (PsA). Psoriasis also is associated with numerous comorbidities. Despite recent advances, there remains a need for orally-delivered psoriasis drugs and other treatment alternatives to biologics, which can be accompanied by side effects that significantly impact activities of daily living, and may lose their effectiveness over time. About 505(b)(2) Development Approach Under the FDA’s 505(b)(2) development approach, a drug candidate’s road to market approval can be significantly shortened and conducted at a much reduced cost. Long-term safety data from a reference drug may be relied upon for approval, and potentially only one pivotal Phase 3 study, enrolling a smaller number of patients than is typical, may be required to establish efficacy. For more information about the FDA’s 505(b)(2) development program, please visit: http://www.fda.gov/downloads/Drugs/…/Guidances/ucm079345.pdf About Cellceutix Headquartered in Beverly, Massachusetts, Cellceutix is a publicly-traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Cellceutix’s psoriasis drug candidate Prurisol completed a Phase 2 trial and Cellceutix has now launched a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its plans for a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of oral mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (“superbugs”). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed for the first four patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), a type of Inflammatory Bowel Disease (IBD). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com. Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning projected timelines for the initiation and completion of clinical trials, our future drug development plans, other statements regarding future product developments, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause Cellceutix’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Time to update your DD on this one. Brilacidin making headway, Kevetrin getting back on track. Prurisol double blind interim data due within the next month or so.
RSI crosses above the oversold line (30) with positive bias. Might be the time to buy. http://www.allotcbb.com/quote.php?symbol=ctix
https://finance.yahoo.com/news/cellceutix-completes-patient-enrollment-final-133000486.html On deck also is interim data for Prurisol. Nice potential through the summer imo.
May 10, 2017 Corporate Cellceutix Provides Corporate Update; Significant Milestones Ahead as Multiple Mid-Phase Clinical Trials Set to Conclude Philip Drake May 10, 2017 Corporate BEVERLY, MA – May 10, 2017 (GLOBE NEWSWIRE) Cellceutix Corporation, (OTCQB: CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory and antibiotic applications, today is pleased to provide a corporate update on current operations and upcoming clinical milestones across its pipeline of First-in-Class drug candidates, Prurisol, Kevetrin and Brilacidin, as summarized in our recent Quarterly Report (Form 10-Q), available for download at the link below. http://www.cellceutix.com/financials/ Clinical Highlights and Upcoming Milestones · This week Cellceutix anticipates enrolling the final patients for the Brilacidin 42-day Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS) clinical study. · Between patients already enrolled and those presently in screening, Cellceutix has reached over 70 percent of the anticipated number of trial participants in its Phase 2b trial of Prurisol for the treatment of moderate-to-severe chronic plaque psoriasis. Interim analysis top-line results are expected to be available during the third quarter of calendar year 2017. · Interim analysis of patients in the Phase 2 trial of Brilacidin-Oral Mucositis (OM) who received at least 55 Gy cumulative units of radiation showed that Brilacidin markedly reduced the rate of Severe OM (WHO Grade ≥ 3): Active Arm (Brilacidin): 2 of 9 patients (22.2 percent); Control Arm (Placebo): 7 of 10 patients (70 percent). · Concurrent with the Phase 2 clinical trial of intravenous-administered Kevetrin for late-stage ovarian cancer, toxicology studies are ongoing with the purpose of developing an oral formulation of Kevetrin for treating solid tumors. Currently, there are no approved p53-modulating cancer drugs, much less in pill form. Prurisol—Psoriasis: Interim Analysis of Phase 2b trial (3Q2017). The ongoing randomized, double-blind, parallel-group and placebo-controlled study (see NCT02949388) increases the total daily oral dosing of Prurisol from a previous high of 200 mg, which earlier was shown to be well-tolerated and efficacious, to include oral Prurisol 300 mg per day, oral Prurisol 400 mg per day, and placebo (3:1:3 randomization). Enrolling approximately 189 patients with moderate-to-severe chronic plaque psoriasis, treatment duration is 12 weeks (84 days). Interim analysis is planned at 6 weeks. Currently, between patients already enrolled and those presently in screening, the Company has reached over 70 percent of the anticipated number of trial participants. Efficacy is being evaluated using the Psoriasis Area and Severity Index (PASI). Cellceutix believes now is an opportune time to develop an oral treatment for psoriasis. Currently approved treatments, including injectable biologics, are limited, with many options costly, not easily administered, associated with undesirable side-effects and/or diminishing effectiveness over time. A novel psoriasis drug, particularly one that is oral, safe and effective, which could expand patient and physician choices for treatment, likely would command significant market value. Learn more here: http://www.cellceutix.com/prurisol-1/ Kevetrin—Ovarian Cancer: Completion of Phase 2a trial (2H2017). The ongoing open-label study (see NCT03042702) is evaluating intravenous (IV) administration of Kevetrin 3 times per week, over 3 weeks, at an initial dose of 250mg/m2, with dose escalation in the 2nd cohort, in patients with platinum-resistant ovarian cancer. Modulation of the p53 pathway to further inform Kevetrin’s mechanism of action (MOA) is being measured via various RNA and protein biomarkers. Endpoints will include safety, efficacy (based on RECIST criteria) and pharmacodynamics. Running in parallel, the Company continues to make substantial progress in developing Kevetrin as an oral formulation. Preliminary bioavailability and other laboratory studies are encouraging and support its potential as an oral formulation. Currently there are no approved p53-modulating drugs, much less in pill form. An oral formulation of Kevetrin one day could position the drug candidate as a go-to cancer treatment. Learn more here: http://www.cellceutix.com/kevetrin-1/ Brilacidin—Oral Mucositis: Completion of Phase 2 trial (2H2017). The ongoing randomized, double-blind, placebo-controlled study (see NCT02324335) is evaluating Brilacidin as an oral rinse, 3 times daily for 7 weeks, to prevent and control Oral Mucositis (OM) in patients receiving chemoradiation therapy for Head and Neck Cancer. Even though over 450,000 patients in the U.S. suffer from this condition, presently there are no approved drugs for the treatment of OM in this population, with only limited palliative care options available. In March 2017, preliminary interim analysis revealed that Brilacidin markedly reduced the occurrence of Severe OM, defined as Grade ≥ 3 on the World Health Organization OM Grading Scale—only 2 of 9 patients (22.2%) receiving Brilacidin developed Severe OM compared to 7 of 10 (70%) patients on placebo. Cellceutix’s goal with this trial is to show that Brilacidin has dual functionality in preventing the onset of the condition and shortening the duration of OM, an accomplishment no other pharmaceutical company has achieved. Brilacidin—Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS): Completion of Phase 2a trial (2Q2017). The ongoing open-label, proof-of-concept trial includes enrolling 18 patients treated with Brilacidin divided evenly into three cohorts (6 patients per cohort)—Cohort A (50 mg); Cohort B (100 mg); Cohort C (200 mg). In March 2017, after Cohorts A and B were completed (presently, three patients in Cohort C have completed their treatment), Cellceutix released interim results. The Primary Efficacy Endpoint of Clinical Remission (accounting for Stool Frequency, Rectal Bleeding and Endoscopy Findings subscores) was met by 50 percent of patients in Cohort A (3 of 6) and 50 percent of patients in Cohort B (3 of 6); all 6 of the remaining patients in Cohorts A and B had a Partial Response, as they met 2 of the 3 specified criteria. Brilacidin was generally well-tolerated. Patient Quality of Life (as assessed by the Short Inflammatory Bowel Disease Questionnaire, SIBDQ) showed notable improvements in all 12 patients. Limited systemic exposure to Brilacidin was demonstrated as measured by plasma Brilacidin concentrations. These data, along with the OM findings, suggest that other inflammatory conditions may, likewise, be treated locally and efficaciously with Brilacidin. Learn more here: http://www.cellceutix.com/brilacidin-1/ Financial Highlights Cash Position—As of March 31, 2017, the Company had approximately $5.6 million in cash and $16 million remaining available for stock sales under the terms of the purchase agreement with Aspire Capital, compared to $6.3 million of cash as of June 30, 2016. Shelf Registration—The Company has in place an effective shelf registration statement on Form S-3, registering the sale of up to $75 million of the Company’s securities, with approximately $42.8 million remaining available. Management Discussion—The Company anticipates that future budget expenditures will be approximately $14 million over the next 12 months, including approximately $10 million for clinical trials. Management believes that financing available from Aspire Capital and under the Company’s effective Form S-3 shelf registration statement as well as any potential future Form S-1 filing to register the sale of its securities will be sufficient to fund the Company’s operations for the next 12 months. “We are extremely proud of our accomplishments to date and are thrilled at the company’s prospects going forward into the latter half of 2017,” said Leo Ehrlich, Chief Executive Officer of Cellceutix. “Within a matter of months, we anticipate completing multiple mid-phase clinical trials for indications in areas with serious unmet medical needs. Based on highly encouraging clinical data received so far, we look forward to sharing complete clinical results with shareholders, members of the pharmaceutical industry interested in our drug candidates, and the public at large, to further establish the true potential of our clinical pipeline.” “Much-needed drugs and tremendous value creation await patients and shareholders alike should we continue to deliver compelling trial results,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Cellceutix. Upcoming Events Cellceutix reminds shareholders and other interested parties of two upcoming events. First, on June 8, 2017, at 11AM EST, the Company will hold a live shareholder and investor conference call. We are fielding questions in advance, which may be submitted by emailing [email protected] and must be received by June 1, 2017 at 5pm EST. Dial-in instructions for participants will be announced one week prior. Second, the Company will be presenting topline findings from the Brilacidin-UP/UPS trial as well as additional interim data from its Phase 2 trial of Brilacidin for Oral Mucositis at Drug Discovery and Therapy World Congress 2017, to be held July 10 – 13, 2017, in Boston. More details to come. Alerts Sign-up for Cellceutix email alerts is available at: www.cellceutix.com/email-alerts
Technically, CTIX has been showing support at 0.8095 and resistance at 1.10. Bullish technical buying signal. http://www.allotcbb.com/quote.php?symbol=ctix
NO SPLIT. Cellceutix Announces Company Name Change to Innovation Pharmaceuticals Inc. Corporate BEVERLY, Mass., June 7, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), an emerging biopharmaceutical company, is pleased to announce to shareholders, and the public at large, that it is changing its name to Innovation Pharmaceuticals Inc. (IPI) and has received a new Committee on Uniform Securities Identification Procedures (CUSIP) number of 45782D 100. Innovation Pharmaceuticals more accurately describes the innovative nature of our first-in-class pipeline of mid-stage drug candidates. These changes will have no impact on the marketability of the Company’s securities, or the ability to trade the common stock through brokerage firms. Stockholders of the Company are not required to exchange their stock certificates in connection with the name change. The Company’s common stock will continue to trade under stock symbol “CTIX” on OTCQB until market close on June 8, 2017. Trading on the OTCQB under the new Innovation Pharmaceuticals name and ticker symbol “IPIX” will begin at market open on June 9, 2017. The Company’s new website address will change to www.IPharmInc.com. In the interim, the Company will maintain www.cellceutix.com. The name change will be discussed at the upcoming live shareholder and investor conference call, to be held on Thursday, June 8, 2017, at 11am EDT. Senior Company management will be responding to recently posed questions submitted by email. Live call-in questions will also be addressed. Below are call-in details for the conference call: Title: Innovation Pharmaceuticals Shareholder and Investor Conference Call Presentation Type: Audio Webcast Event Date: Thursday, June 8, 2017, at 11am EDT Call-in Numbers: 866-682-6100 / 862-255-5401 Event Link: http://www.investorcalendar.com/event/15776 ====================================================== Name change should be posted to The Daily List shortly. http://otce.finra.org/DailyList Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Effective June 5, 2017, the registrant changed its corporate name from Cellceutix Corporation to Innovation Pharmaceuticals Inc. (the “Company”). In accordance with Section 92A.180 of the Nevada Revised Statutes, stockholder approval of the name change was not required. In connection with Rule 6490 of the Financial Industry Regulatory Authority (“FINRA”) and Rule 10b-17 of the Securities Exchange Act of 1934, as amended, the Company submitted an issuer company-related action notification form to FINRA notifying FINRA of the name change and FINRA has confirmed that it will process the name change, effective at the open of business on June 9, 2017. In connection with the name change, the CUSIP number for the Company’s Class A common stock will change to 45782D 100. The Company’s Class A common stock will continue to be quoted on the OTCQB market but will trade under a new ticker symbol, “IPIX”. A copy of the Company’s Articles of Incorporation, as amended, is filed herewith as Exhibit 3.1. Item 7.01 Regulation FD Disclosure. On June 7, 2017, the Company issued a press release announcing the name change. The full text of the press release is furnished with this Form 8-K as Exhibit 99.1 and incorporated by reference herein. The information in this Current Report on Form 8-K under Item 7.01, including the accompanying press release, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by reference to such filing. Item 9.01 Financial Statements and Exhibits. https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm AMENDED AND RESTATED ARTICLES OF INCORPORATION OF INNOVATION PHARMACEUTICALS INC. ARTICLE I The name of the corporation (hereinafter referred to as the “Corporation”) is: “Innovation Pharmaceuticals Inc.” ARTICLE II The address of the Corporation’s registered office in the State of Nevada is United Corporate Services, Inc., in the City of Carson City, County of Carson. The name of the Corporation’s registered agent at such address is 202 South Minnesota Street, Carson City, Nevada 89703. ARTICLE III (a) Authorized Capital Stock. (i) The total number of shares of stock that the Corporation shall have authority to issue is 410,000,000, consisting of (ii) 300,000,000 shares of Class A Common Stock, par value $0.0001 per share (“Common Stock”) and (iii) 100,000,000 shares of Class B Common Stock, par value $0.0001 per share (“Common Stock”) (iv) 10,000,000 shares of Preferred Stock, par value $0.001 per share (“Preferred Stock”). The holders of shares of the Class A Common Stock shall not have the right to convert their shares of Class A Common Stock into any other securities. The holders of shares of the Class B Common Stock at their election shall have the right, at any time or from time to time, to convert any or all of their shares of Class B Common Stock into shares of Class A Common Stock, on a one to one basis, by delivery to the Corporation of the certificates representing such shares of Class B Common Stock duly endorsed for such conversion. Any shares of the Class B Common Stock that are transferred will automatically convert into shares of the Class A Common Stock, on a one to one basis, effective as of the date on which certificates representing such shares are presented for transfer on the books of the Corporation. 1 VOTING RIGHTS Subject to the limitations provided by law and subject to any voting rights applicable to shares of the Preferred Stock, the Class A Common Stock and the Class B Common Stock shall have the sole right and power to vote on all matters on which a vote of shareholders is to be taken. In all matters, with respect to actions both by vote and by consent, each holder of shares of the Class A Common Stock shall be entitled to cast one vote in person or by proxy for each share of Class A Common Stock standing in such holder’s name on the transfer books of the Corporation; and each holder of shares of the Class B Common Stock shall be entitled to cast ten votes in person or by proxy for each share of Class B Common Stock standing in such holder’s name on the transfer books of the Corporation. Except as otherwise provided above and subject to the limitations provided by law and subject to any voting rights applicable to shares of the Preferred Stock, the holders of shares of the Class A Common Stock and Class B Common Stock shall vote together as a single class, together with the holders of any shares of the Preferred Stock which are entitled to vote, and not as a separate class. (b) Preferred Stock. Preferred Stock may be issued from time to time in one or more series. The Board of Directors is hereby authorized to provide for the issuance of shares of Preferred Stock in series and, by filing a certificate pursuant to the Nevada Revised Statutes (“N.R.S.”) (hereinafter, along with any similar designation relating to any other class of stock that may hereafter be authorized, referred to as a “Preferred Stock Designation”), to establish from time to time the number of shares to be included in each such series, and to fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations and restrictions thereof. The authority of the Board of Directors with respect to each series shall include, but not be limited to, determination of the following: (i) The designation of the series, which may be by distinguishing number, letter or title; (ii) The number of shares of the series, which number the Board of Directors may thereafter (except where otherwise provided in the Preferred Stock Designation) increase or decrease (but not below the number of shares thereof then outstanding); (iii) The amounts payable on, and the preferences, if any, of shares of the series in respect of dividends, and whether such dividends, if any, shall be cumulative or noncumulative; (iv) Dates on which dividends, if any, shall be payable; (v) The redemption rights and price or prices, if any, for shares of the series; (vi) The terms and amount of any sinking fund provided for the purchase or redemption of shares of the series; (vii) The amounts payable on and the preferences, if any, of shares of the series in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Corporation; (viii) Whether the shares of the series shall be convertible into or exchangeable for shares of any other class or series, or any other security, of the Corporation or any other corporation, and, if so, the specification of such other class or series of such other security, the conversion or exchange price or prices or rate or rates, any adjustments thereof, the date or dates at which such shares shall be convertible or exchangeable and all other terms and conditions upon which such conversion or exchange may be made; (ix) Restrictions on the issuance of shares of the same series or of any other class or series; (x) The voting rights, if any, of the holders of shares of the series. 2 (c) Common Stock. The Common Stock shall be subject to the express terms of the Preferred Stock and any series thereof. Each share of Common Stock shall be equal to each other share of Common Stock. Except as may be provided in these Amended Articles of Incorporation or in a Preferred Stock Designation, the holders of shares of Common Stock shall be entitled to one vote for each such share upon all questions presented to the stockholders. ARTICLE IV The Board of Directors is hereby authorized to create and issue, whether or not in connection with the issuance and sale of any of stock or other securities or property of the Corporation, rights entitling the holders thereof to purchase from the Corporation shares of stock or other securities of the Corporation or any other corporation. The times at which and the terms upon which such rights are to be issued will be determined by the Board of Directors and set forth in the contracts or instruments that evidence such rights. The authority of the Board of Directors with respect to such rights shall include, but not be limited to, determination of the following: (a) The initial purchase price per share or other unit of the stock or other securities or property to be purchased upon exercise of such rights. (b) Provisions relating to the times at which and the circumstances under which such rights may be exercised or sold or otherwise transferred, either together with or separately from, any other stock or other securities of the Corporation. (c) Provisions that adjust the number or exercise price of such rights or amount or nature of the stock or other securities or property receivable upon exercise of such rights in the event of a combination, split or recapitalization of any stock of the Corporation, a change in ownership of the Corporation’s stock or other securities or a reorganization, merger, consolidation, sale of assets or other occurrence relating to the Corporation or any stock of the Corporation, and provisions restricting the ability of the Corporation to enter into any such transaction absent an assumption by the other party or parties thereto of the obligations of the Corporation under such rights. (d) Provisions that deny the holder of a specified percentage of the outstanding stock or other securities of the Corporation the right to exercise such rights and/or cause the rights held by such holder to become void. (e) Provisions that permit the Corporation to redeem or exchange such rights. (f) The appointment of a rights agent with respect to such rights. ARTICLE V (a) Subject to the rights of the holders of any series of Preferred Stock or any other series or class of stock as set forth in these Amended Articles of Incorporation, to elect additional directors under specified circumstances, the number of directors of the Corporation shall be fixed by the By-laws of the Corporation and may be increased or decreased from time to time in such a manner as may be prescribed by the By-laws. (b) Unless and except to the extent that the By-laws of the Corporation shall so require, the election of directors of the Corporation need not be by written ballot. 3 ARTICLE VI The Corporation may in its By-laws confer powers upon the Board of Directors in addition to the foregoing and in addition to the powers and authorities expressly conferred upon the Board of Directors by applicable law. ARTICLE VII (a) Each person who is or was or had agreed to become a director or officer of the Corporation, or each such person who is or was serving or who had agreed to serve at the request of the Board of Directors or an officer of the Corporation as a director, officer or trustee of another corporation, partnership, joint venture, trust or other enterprise (including the heirs, executor, administrators or estate of such person), shall be indemnified by the Corporation, in accordance with the By-laws of the Corporation, to the fullest extent permitted from time to time by the N.R.S. as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than said law permitted the Corporation to provide prior to such amendment) or any other applicable laws as presently or hereafter in effect. (b) The Corporation may, by action of the Board of Directors or through the adoption of By-laws, provide indemnification to employees and agents of the Corporation, and to persons serving as employees or agents of another corporation, partnership, joint venture, trust or other enterprise, at the request of the Corporation, with the same scope and effect as the foregoing indemnification of directors and officers. The Corporation shall be required to indemnify any person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person only if such proceeding (or part thereof) was authorized by the Board of Directors or is a proceeding to enforce such person’s claim to indemnification pursuant to the rights granted by these Amended Articles of Incorporation or otherwise by the Corporation. (c) The right to indemnification conferred in this Article VII shall be a contract right and shall include the right to be paid by the Corporation the expenses incurred in defending any such proceeding in advance of its final disposition, such advances to be paid by the Corporation within twenty (20) days after the receipt by the Corporation of a statement or statements from the claimant requesting such advance or advances from time to time; provided, however, that if the N.R.S. requires, the payment of such expenses incurred by such a person in his or her capacity as such a director or officer of the Corporation in advance of the final disposition of a proceeding, shall be made only upon delivery to the Corporation of an undertaking by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified under this Article VII or otherwise. (d) Without limiting the generality or the effect of the foregoing, the Corporation may enter into one or more agreements with any person that provide for indemnification greater or different than that provided in this Article VII. (e) Neither any amendment or repeal of any Section of this Article VII, nor the adoption of any provision of these Amended Articles of Incorporation or the By-laws of the Corporation inconsistent with this Article VII, shall adversely affect any right or protection of any director, officer, employee or other agent established pursuant to this Article VII existing at the time of such amendment, repeal or adoption of an inconsistent provision, including without limitation by eliminating or reducing the effect of this Article VII, for or in respect of any act, omission or other matter occurring, or any action or proceeding accruing or arising (or that, but for this Article VII, would accrue or arise), prior to such amendment, repeal or adoption of an inconsistent provision. 4 ARTICLE VIII (a) The liability of the directors of the Corporation for monetary damages shall be eliminated to the fullest extent permitted by the N.R.S., as now or hereafter in effect. If the N.R.S. is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated to the fullest extent permitted by the N.R.S., as so amended. (b) Neither any amendment or repeal of any Section of this Article VIII, nor the adoption of any provision of these Amended Articles of Incorporation or the By-laws of the Corporation inconsistent with this Article VIII, shall adversely affect any right or protection of any director established pursuant to this Article VIII existing at the time of such amendment, repeal or adoption of an inconsistent provision, including without limitation by eliminating or reducing the effect of this Article VIII, for or in respect of any act, omission or other matter occurring, or any action or proceeding accruing or arising (or that, but for this Article VIII, would accrue or arise), prior to such amendment, repeal or adoption of an inconsistent provision. ARTICLE IX Except as may be expressly provided in these Amended Articles of Incorporation, the Corporation reserves the right at any time and from time to time to amend, alter, change or repeal any provision contained in these Amended Articles of Incorporation or a Preferred Stock Designation, and any other provisions authorized by the laws of the State of Nevada at the time in force may be added or inserted, in the manner now or thereafter prescribed herein or by applicable law, and all rights, preferences and privileges of whatsoever nature conferred upon stockholders, directors or any other persons whomsoever by and pursuant to these Amended Articles of Incorporation in its present form or as hereafter amended are granted subject to the right reserved in this Article IX; provided, however, that any amendment or repeal of Article VII or Article VIII of these Amended Articles of Incorporation shall not adversely affect any right or protection existing hereunder in respect of any act or omission occurring prior to such amendment or repeal; and provided further that no Preferred Stock Designation shall be amended after the issuance of any shares of the series of Preferred Stock created thereby, except in accordance with the terms of such Preferred Stock Designation and the requirements of applicable law. https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_ex31.htm
